Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring
Cogent Biosciences (NASDAQ:COGT) Price Target Cut to $23.00 by Analysts at Needham & Company LLC
Cogent Biosciences (NASDAQ:COGT – Get Rating) had its price target reduced by Needham & Company LLC from $24.00 to $23.00 in a research note released on Wednesday, The Fly reports. Needham & Company L
Cogent Biosciences, Inc. (NASDAQ:COGT) to Post FY2023 Earnings of ($2.52) Per Share, Jefferies Financial Group Forecasts
Cogent Biosciences, Inc. (NASDAQ:COGT – Get Rating) – Analysts at Jefferies Financial Group cut their FY2023 earnings per share estimates for Cogent Biosciences in a research note issued on Tuesday
Q1 2023 EPS Estimates for Cogent Biosciences, Inc. (NASDAQ:COGT) Reduced by Analyst
Cogent Biosciences, Inc. (NASDAQ:COGT – Get Rating) – Equities researchers at SVB Leerink dropped their Q1 2023 EPS estimates for Cogent Biosciences in a note issued to investors on Tuesday, March
Cogent Biosciences Price Target Maintained With a $26.00/Share by Guggenheim
Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM), Aclaris Therapeutics (ACRS) and Cogent Biosciences (COGT)
Needham Adjusts Price Target on Cogent Biosciences to $23 From $24, Keeps Buy Rating
07:44 AM EDT, 03/15/2023 (MT Newswires) -- Cogent Biosciences (COGT) has an average rating of buy and price targets ranging from $18 to $28, according to analysts polled by Capital IQ.
Cogent Biosciences Price Target Cut to $23.00/Share From $24.00 by Needham
Cogent Biosciences Is Maintained at Buy by Needham
Needham Maintains Buy on Cogent Biosciences, Lowers Price Target to $23
Needham analyst Ami Fadia maintains Cogent Biosciences with a Buy and lowers the price target from $24 to $23.
No Stock Yet